Drug intelligence / Profile preview

nidufexor

Development stage: Phase 2
Lead developer: Novartis
Modality: Small Molecules
Administration: Oral

Overview

Nidufexor is a novel, orally administered small molecule that acts as a partial agonist of the farnesoid X receptor (FXR). FXR is a nuclear receptor involved in the regulation of bile acid, lipid, and glucose metabolism. Nidufexor was developed to target chronic liver diseases such as nonalcoholic steatohepatitis (NASH) and diabetic nephropathy. Preclinical studies demonstrated that nidufexor modulates FXR-dependent gene expression, leading to reduced hepatic steatosis, inflammation, and fibrosis. It has advanced to Phase 2 clinical trials for NASH and diabetic nephropathy[6][8].

Targets

FXR (Farnesoid x-activated receptor)

Beyond the preview

Go deeper on nidufexor.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on nidufexor.

Explore the full profile